Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Angiogenesis and Vascular Targeting in Ewing Sarcoma A Review of Preclinical and Clinical Data CANCER DuBois, S. G., Marina, N., Glade-Bender, J. 2010; 116 (3): 749-757

Abstract

Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach.

View details for DOI 10.1002/cncr.24844

View details for Web of Science ID 000274169200023

View details for PubMedID 20029966